[A20-06] Ivacaftor (combination with tezacaftor/ivacaftor, cystic fibrosis, 12 years and older, with F508del mutation, heterozygous) - Addendum to Commission A19-71
Last updated 20.02.2020
Commission awarded on 07.01.2020 by the Federal Joint Committee (G-BA).
Airways and respiratory system
Cystic fibrosis in patients aged 12 years and older who are heterozygous for the F508del mutation in the CFTR gene
Conclusion of dossier assessment A19-71 unchanged
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
|A19-71||Ivacaftor (combination with ivacaftor/tezacaftor, cystic fibrosis, 12 years and older, with F508del mutation, heterozygous) - Benefit assessment according to §35a Social Code Book V||Commission completed|